2012 Volume 3 Issue 2 Pages 145-150
【Objective】We analyzed the current status of acute blood purification therapy in children in Japan. 【Method】The subjects were 50 children (neonates and infants) weighing 20kg or less who received acute blood purification (ABP) therapy at 15 centers between July 2007 and July 2008. Therapeutic conditions for ABP and 28-day survival rates were investigated. 【Results】There was a high incidence of sepsis, inborn errors of metabolism, and acute renal failure. A 6- to 9-Fr. double-lumen catheter in the internal jugular vein was used for vascular access. A module of 0.3m2 was generally used. Nafamostat mesilate was administered as an anticoagulant in 86％ of the cases. Packed red cells were added to the priming solution in children weighing 9kg or less. The volume of blood to be purified was adjusted appropriately for children’s weight and disease condition. The 28-day survival was 80％. 【Conclusion】This study showed that ABP therapy is performed in almost the same way. In the future, standardization of ABP therapy is required in children, for example by defining optimal therapeutic conditions for each disease condition.
